

Antiviral-Indication Expansions: Preclinical & Clinical Compound/Indications

Investigational: Antiviral compounds in clinical phase development for a different virus disease indication.


Approved: Antiviral compounds approved for treatment of a different virus disease indication.



- ▶ 6 of these antivirals (favipiravir, remdesivir, molnupiravir, amantadine, oseltamivir, & zanamivir) are approved for treatment of COVID-19 and/or Influenza.
 - ▶ Valganciclovir and cidofovir are approved for treating CMV disease.
- ▶ Favipiravir has the most indication expansions under evaluation (9) followed by remdesivir (6).

*As of July 12, 2024


Preclinical Compound/Indications by Stage of Preclinical Development (Non-COVID-19; N=56)*



► Compound/Indications span the various stages of preclinical development.

*As of July 12, 2024

COVID-19 Compounds by Stage of Preclinical Development (N=76)*



*As of July 12, 2024



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested
in engaging
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance